/ Moderna
/ Market Analysis
Moderna’s Shares Gain in Premarket as New Flu Shot Shows Promising Results
Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.
June 30, 2025
Why is Moderna’s Stock Gaining in Premarket Trading Today?
Moderna stock jumped in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine.
June 02, 2025
Trump Admin. Reconsiders $590M Funding for Moderna’s Bird Flu Vaccine
The Trump administration is reconsidering a $590 million contract with Moderna for bird flu vaccine development.
February 27, 2025
Moderna Cuts 2025 Sales Forecast Amid Low Vaccine Demand, Stock Plummets
Moderna has lowered its 2025 sales forecast due to decreased demand for its Covid and RSV vaccines.
January 13, 2025
Nasdaq-100 Shakeup: 3 Stocks that Can Gain
Three stocks have their price targets above current price levels.
December 16, 2024More from The Tokenist / Moderna
Back to 
